Clinical trial
Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)
NCT00252967 · Emory University, Other · Terminated
Key facts
| NCT number | NCT00252967 |
|---|---|
| Title | Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF) |
| Official title | Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF) |
| Lead sponsor | Emory University, Other |
| Collaborators | Pfizer Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation, Inflammation |
| Intervention type | Drug |
| Interventions | Atorvastatin, Placebo |
| Enrollment | 64 |
| Start date | Oct 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Oct 1, 2009 |
| First posted | Nov 15, 2005 |
| Last update posted | Sep 3, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: